Similarly, Schrock et al. demonstrated that methylation levels of short stature homeobox 2 (SHOX2) and septin 9 (SEPT9) quantified in plasmatic ctDNA of patients before treatment were significantly higher with respect to control group (AUC SEPT9 = 0.79, 95% CI, 0.74–0.85; AUC SHOX2 = 0.80, 95% CI, 0.75–0.85), while their evaluation during follow-up showed a significant correlation with vascular and lymphatic invasion, tumor staging, and LNM. Here, SEPTIN9 is linked to neoplasm.